JP Morgan Chase’s Anebulo Pharmaceuticals ANEB Stock Holding History

JP Morgan Chase’s Portfolio ANEB Stock Details ANEB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-2,253	Closed	-$2.28K	–	7506
2025 Q4	$2.28K	Buy	2,253 +115	+5%	+$262	﹤0.01%	6924
2025 Q3	$5.34K	Buy	+2,138	New	+$5.03K	﹤0.01%	6764
2025 Q2	–	Sell	-8	Closed	-$10	–	7044
2025 Q1	$10	Sell	8 -1	-11%	-$1	﹤0.01%	7184
2024 Q4	$15	Hold	9	–	–	﹤0.01%	7292
2024 Q3	$17	Sell	9 -1	-10%	-$2	﹤0.01%	7260
2024 Q2	$27	Buy	10 +1	+11%	+$3	﹤0.01%	7129
2024 Q1	$26	Buy	+9	New	+$23	﹤0.01%	7135
2023 Q2	–	Sell	-16	Closed	–	–	6893
2023 Q1	$0	Buy	+16	New	+$45	﹤0.01%	6658

JP Morgan Chase's ANEB Position: Q1 2026 in Review

JP Morgan Chase sold out of Anebulo Pharmaceuticals (ANEB) in Q1 2026, closing a stake of 2,253 shares — an estimated $2.28K sold.

JP Morgan Chase first reported a position in ANEB in Q1 2023 and held it in 8 quarters. The position peaked at $5.34K in Q3 2025. 0 funds tracked by Wall St. Rank hold ANEB as of Q1 2026.

JP Morgan Chase reported no remaining Anebulo Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
JP Morgan Chase sold 2,253 Anebulo Pharmaceuticals shares in Q1 2026, an estimated $2.28K.
JP Morgan Chase first reported a position in Anebulo Pharmaceuticals in Q1 2023 and held it in 8 quarters.
JP Morgan Chase's Anebulo Pharmaceuticals position peaked at $5.34K in Q3 2025.
0 funds tracked by Wall St. Rank held Anebulo Pharmaceuticals as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.